• 대한화학회지
• /
• 제47권5호
• /
• pp.530-532
• /
• 2003

• 약학회지
• /
• 제43권4호
• /
• pp.442-446
• /
• 1999

The synthesis and antimicrobial activity of N-substituted glycyl derivatives of Norfloxacin were described. Norfloxacin was treated with chloroacetyl chloride to yield chloroacetyl norfloxacin (1). This compounds was treated with alkylamines to obtain quinolone carboxylic acids (2-6), which were reacted with pivaloyloxymethyl chloride to get pivaloyloxymethyl quinolone carboxylates (7-11). Free carboxylic quinolones (2-6) showed little stronger activities to their pivaloyloxymethyl esters (7-11). In quinolone analogues, longer alkyl chain compounds showed stronger activities than shorter one.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1992년도 제1회 신약개발 연구발표회 초록집
• /
• pp.17-17
• /
• 1992

항균성 물질을 이용한 화학 요법의 역사는 1930 년대 초 술폰아미드의 발견으로부터 비롯되었고, 페니실린의 발견 이래 $\beta$-lactam 계 항생제가 주종을 이루고 있다. 1963년 Lesher 와 Gruett 에 의해 합성된 nalidixic acid 가 요도염 치료제로 임상에 사용된 이후 이와 유사한 구조를 갖는 항균제 개발에 많은 연구가 진행되어 제 1세대, 제 2세대의 quinolone 개발에 이어 1950년대에 들어 제 3세대 quinolone의 개발이 활발히 진행되어 왔다. 제 3세대 항생제는 C-6 위치에 F기를 도입한 것으로 연구의 진행 방향은 항균력의 향상과 체내에서의 지속 시간의 연장, 경구 투여시 흡수로의 증가와 독성의 약화를 위한 것이다. 본 연구는 quinolone의 기본 골격을 유지하면서 C-7 위치에 새로운 group을 도입하여 그에 대한 항균력을 측정하여 새로운 quinolone계 항생제의 개발을 시도하였다.

• 생명과학회지
• /
• 제13권6호
• /
• pp.943-949
• /
• 2003

7번 위치에 하롤겐이 치환된 여로종류의 퀴놀론 모핵과 시스 또는 트란스-3-아미노-4-메틸오메틸피롤리딘을 반응시켜 7-(시스 또는 트란스-3-아미노-4-메틸티오메틸피롤리디닐) 퀴롤론-3-카르복실산의 신규 항균제를 합성하였다. 새롭게 합성된 퀴놀론의 약효는 그람양성균에 대해 대조물질인 시프로플로삭신보다 매우 탁월하였고, 녹농균이외의 그람음성균에 대해서도 대조물질과 거의 유사하였다. 그리고 임상에서 문제가 되고 있는 메티실린 내성 포도상구균(MRSA)에 대한 신규 퀴놀론의 약효는 더욱더 향상되어진 것으로 나타났다.

• Biomolecules & Therapeutics
• /
• 제15권2호
• /
• pp.102-107
• /
• 2007

Cimetidine, a substrate for P-glycoprotein (P-gp), is a well known drug interacting with a variety of drugs and results in alteration of pharmacokinetic parameters by concomitant administration. The aim of present study was to investigate whether cimetidine affects the transport of various quinolone antibiotics in human colorectal cancer cell line (Caco-2) system which has been typically used to investigate drug transport via P-gp. The apparent permeability coefficients (P$_{app}$) value of 9 quinolone antibiotics in the co-treatment with cimetidine was examined. Apical to basolateral (AP-to-BL) transport of fleroxacin in the co-treatment with cimetidine was increased to 1.5-fold (p<0.01) compared with that of fleroxacin alone, whereas basolateral to apical (BL-to-AP) transport of fleroxacin was decreased to 0.83-fold significantly (p<0.05). Ofloxacin was decreased to 0.8-fold (p<0.01) and 0.72-fold (p<0.01) significantly in AP-to-BL and BL-to-AP direction, respectively by cimetidine cotreatment. The P$_{app}$ values of gatifloxacin, moxifloxacin, ciprofloxacin and rufloxacin also were changed by cimetidine. These results have a potential that cimetidine influences on the pharmacokinetics of quinolone antibiotics. It suggests that careful drug monitoring and dosage adjustment may be necessary during the co-administration of quinolone antibiotics with cimetidine.

• Journal of Microbiology and Biotechnology
• /
• 제26권9호
• /
• pp.1605-1612
• /
• 2016

Quinolone-resistant Salmonella strains were isolated from patient samples, and several quinolone-sensitive strains were used to analyze mutations in the quinolone resistance-determining region (QRDR) of gyrA, gyrB, parC, and parE and to screen for plasmid-mediated quinolone resistance. Among the 21 strains that showed resistance to nalidixic acid and ciprofloxacin (MIC 0.125-2.0 μg/ml), 17 strains had a mutation in QRDR codon 87 of gyrA, and 3 strains had a single mutation (Ser83 → Phe). Another cause of resistance, efflux pump regulation, was studied by examining the expression of acrB, ramA, marA, and soxS. Five strains, including Sal-KH1 and Sal-KH2, showed no increase in relative expression in an analysis using the qRT-PCR method (p < 0.05). In order to determine the genes involved in the resistance, the Sal-9 isolate that showed decreased susceptibility and did not contain a mutation in the gyrA QRDR was used to make the STM (MIC 8 μg/ml) and STH (MIC 16 μg/ml) ciprofloxacin-resistant mutants. The gyrA QRDR Asp87 → Gly mutation was identified in both the STM and STH mutants by mutation analysis. qRT-PCR analysis of the efflux transporter acrB of the AcrAB-TolC efflux system showed increased expression levels in both the STM (1.79-fold) and STH (2.0-fold) mutants. In addition, the expression of the transcriptional regulator marA was increased in both the STM (6.35-fold) and STH (21.73-fold) mutants. Moreover, the expression of soxS was increased in the STM (3.41-fold) and STH (10.05-fold) mutants (p < 0.05). Therefore, these results indicate that AcrAB-TolC efflux pump activity and the target site mutation in gyrA are involved in quinolone resistance.

• Bulletin of the Korean Chemical Society
• /
• 제28권7호
• /
• pp.1203-1205
• /
• 2007

• 대한화학회지
• /
• 제34권6호
• /
• pp.673-675
• /
• 1990

• 대한화학회지
• /
• 제54권1호
• /
• pp.65-70
• /
• 2010

유색미인 흑남벼(Oryza sativa cv. Heugnambyeo) 미강의 ethylacetate 가용성 용매분획물로부터 NO 생성을 저해시키는 단일화합물을 순수 분리한 후, HREI-MS 및 2D-NMR 분석을 통해 화학구조를 4-carboethoxy-6-methoxy-2-quinolone (1)과 4-carboethoxy-6-hydroxy-2-quinolone (2)으로 명명하였다.

• 생명과학회지
• /
• 제15권3호
• /
• pp.423-426
• /
• 2005

운향과(Rutaceae)인 황백나무(Phellodendron nmurense Rupr.)의 줄기 점 질에서 2종의 isoquinoline 화합물과 1종의 quinolone 화합물을 분리하였다. Isoquinoline 화합물은 thalifoline (2)과 칼슘 방출을 저해하여 혈압조절에 관여하는 berberine (3)으로 구조동정 되었다. 또한 quinolone 화합물은 N-methylatanine (1)로 구조동정 되었다. 이들의 화합물 중에서 N-methylatanine (1)과 thalifoline (2)는 황백나무에서 처음으로 분리하였다.